Answers are grounded in this paper and cite their sources.
Background Waldenstrom macroglobulinemia (WM) is an indolent lymphoma with a long course; advanced age and immunosuppressive treatments may predispose for second primary malignancies (SPM). Methods Consecutive symptomatic, newly diagnosed patients with WM who were diagnosed, treated and followed-up until May 28, 2024 were included in this study. Results 677 symptomatic patients with WM were included in the analysis; their median age was 69 years (range 24-93) and 209 were females (30.9%). Over a median follow-up of 5.32 years (range 0.01-25.61), 58 patients (8.6%) were diagnosed with a SPM. The median time from WM diagnosis to SPM diagnosis was 4.93 years (range 0.07-20.71). The incidence rate (IR) of a SPM per person-year was 0.009, translating to roughly 1 case per 100 person-years. The cumulative incidence (CI) of SPMs, accounting for death due to WM or other causes as a competing event, at 5 and 10 years was 4.0% and 7.2%. Furthermore, 23 patients (3.4%) developed transformation to high grade lymphoma. The median time from WM diagnosis to transformation was 5.36 years (range 0.01-25.6). The IR of transformation per person-year was 0.003, translating to 3 cases per 1000 person-years. The CI of transformation to high-grade lymphoma, accounting for death due to WM or other causes as a competing event, at 5 and 10 years, was 2.1% and 3.4%. Conclusions Data from our prospectively maintained multicenter database revealed that 8.6% and 3.4% of symptomatic patients with WM developed a SPM and disease transformation, respectively, over a median follow-up of 5.3 years. Micro-Abstract In a cohort of 677 patients with symptomatic Waldenström macroglobulinemia (WM), 8.6% developed second primary malignancies (SPM) and 3.4% developed disease transformation to high-grade lymphoma, over a median follow-up of 5.3 years. The cumulative incidence of SPMs accounting for death due to WM or other causes at 5- and 10-years, was 4.0% and 7.2%, respectively, while that of transformation to high-grade lymphoma, was 2.1% and 3.4%, respectively. High LDH levels seemed to increase the risk of transformation (HR=5.57, p <0.001). These findings highlight the risks for SPMs occurence and disease transformation in WM patients and underline the need for long term surveillance.
No takes yet. Share an insight, caveat, or question.
Gavriatopoulou et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: